Cancer treatment failures often stem from the inability to predict which drug combinations will work synergistically rather than simply additively. This limitation has left oncologists relying on trial-and-error approaches that delay effective treatment and expose patients to unnecessary toxicity. A breakthrough proteomics technique now reveals why certain drug pairs succeed where individual compounds fail, potentially transforming how combination therapies are designed and selected.
Researchers developed CoPISA (Combinatorial Proteome Integral Solubility/Stability Alteration analysis) to map protein changes that occur exclusively when specific drugs work together. Testing two rationally designed pairs for acute myeloid leukemia—LY3009120 with sapanisertib, and ruxolitinib with ulixertinib—the method identified "conjunctional targeting" where combinations activate entirely different protein networks than either drug alone. The LY3009120-sapanisertib pair uniquely altered SUMOylation pathways and chromatin organization, while ruxolitinib-ulixertinib specifically disrupted DNA repair checkpoints and mitochondrial function. Crucially, combinations triggered post-translational modifications in key leukemia proteins including NPM1 that neither drug achieved independently.
This represents a fundamental shift from viewing drug combinations as simply stronger versions of single agents. The discovery that effective combinations operate through "AND-gate logic"—requiring both drugs to access certain therapeutic targets—explains why some pairs demonstrate outsized efficacy. For cancer treatment, this could accelerate the rational design of combination regimens and reduce the extensive trial phases currently needed. The approach's ability to identify combination-exclusive targets suggests it could predict therapeutic synergy before clinical testing, potentially revolutionizing precision oncology approaches across cancer types.